NCT06148636 - A Safety Study of 212Pb-VMT-alpha-NET in Patients With Neuroendocrine Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 10, 2023

Primary Completion Date

November 20, 2026

Study Completion Date

November 20, 2027

Conditions

Neuroendocrine TumorsNeuroendocrine Tumor of the LungNeuroendocrine Tumor Grade 1Neuroendocrine Tumor Grade 2Neuroendocrine Tumor of Pancreas

Interventions

DRUG

[212Pb] VMT-α-NET

Up to 2 infusions with \[212Pb\] VMT-α-NET, each infusion separated by at least 8 weeks. During each infusion, the participants also receive an infusion with lysine and arginine (amino acids) to help reduce kidney damage.

DIAGNOSTIC_TEST

[203Pb] VMT-α-NET SPECT/CT

The \[203Pb\] VMT-α-NET SPECT/CT is performed for all participants to determine trial eligibility as well as for the calculations to determine the estimated radiation dose to kidneys. This involves three imaging sessions of about 2 hours each over 2 days. The participants also receive an infusion with lysine and arginine (amino acids) to help reduce kidney damage at the time they receive the injection of . \[203Pb\] VMT-α-NET, a radioactive tracer drug.

Trial Locations (1)

52242

Holden Comprehensive Cancer Center at the University of Iowa, Iowa City